-

Entwistle & Cappucci LLP is Investigating Potential Federal Securities Law Violations in Connection with Cerevel Therapeutics Holdings, Inc. (CERE)

NEW YORK--(BUSINESS WIRE)--Entwistle & Cappucci LLP (“Entwistle & Cappucci”) is investigating potential federal securities law violations on behalf of its clients and other former holders of Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) common stock.

Cerevel was a publicly traded biopharmaceutical company that was acquired by AbbVie, Inc. in August 2024. On October 16, 2023, Cerevel conducted a secondary public stock offering of approximately 19 million shares for $22.81 per share. Less than two months later, AbbVie announced it was acquiring Cerevel for $45.00 per share. Entwistle & Cappucci is investigating claims related to the purchases of Cerevel stock by certain Company insiders.

If you sold Cerevel (NASDAQ: CERE) securities from October 11, 2023 through December 6, 2023, or have other information concerning these issues, please contact attorneys Robert N. Cappucci or Andrew M. Sher at 212-894-7200, or via e-mail at rcappucci@entwistle-law.com or asher@entwistle-law.com.

About Entwistle & Cappucci

Entwistle & Cappucci is a national law firm providing exceptional legal representation to clients globally in the most complex and challenging legal matters. Our practice encompasses all areas of litigation, including securities, antitrust, corporate transactions, general corporate and commercial, creditor’s rights and bankruptcy, corporate governance and fiduciary duty, government affairs, insurance, investigations and white-collar defense. Our clients include public and private corporations, major hedge funds, public pension funds, governmental entities, leading institutional investors, domestic and foreign financial services companies, emerging business enterprises and individual entrepreneurs.

Contacts

Robert N. Cappucci, Esq. (rcappucci@entwistle-law.com)
Andrew M. Sher, Esq. (asher@entwistle-law.com)
Entwistle & Cappucci LLP
www.entwistle-law.com
230 Park Avenue, 3rd Floor
New York, NY 10169
Telephone: (212) 894-7200

Industry:

Entwistle & Cappucci LLP

NASDAQ:CERE
Release Versions
English

Contacts

Robert N. Cappucci, Esq. (rcappucci@entwistle-law.com)
Andrew M. Sher, Esq. (asher@entwistle-law.com)
Entwistle & Cappucci LLP
www.entwistle-law.com
230 Park Avenue, 3rd Floor
New York, NY 10169
Telephone: (212) 894-7200

More News From Entwistle & Cappucci LLP

Entwistle & Cappucci LLP Files Amended Securities Class Action Complaint Against KnowBe4, Inc. and Related Defendants

NEW YORK--(BUSINESS WIRE)--Entwistle & Cappucci LLP today announced that it filed a First Amended Class Action Complaint (“Complaint”) against KnowBe4, Inc. (“KnowBe4”), certain of KnowBe4’s directors, KKR & Co. Inc., Elephant Partners, Vista Equity Partners Management, LLC (“Vista”) and certain of their affiliates (collectively, “Defendants”) on behalf of a class (“Class”) consisting of all persons or entities that: (a) sold shares of KnowBe4 common stock from October 12, 2022 through...

Entwistle & Cappucci LLP Files a Securities Class Action Against KnowBe4, Inc. and Related Defendants

NEW YORK--(BUSINESS WIRE)--Entwistle & Cappucci LLP today announced that its ongoing investigation has led to the filing of a class action (“Action”) against KnowBe4, Inc. (“KnowBe4”), certain of KnowBe4’s directors, KKR & Co. Inc., Elephant Partners, Vista Equity Partners Management, LLC (“Vista”) and certain of their affiliates (collectively, “Defendants”) on behalf of a class (“Class”) consisting of all persons or entities that: (a) sold shares of KnowBe4 common stock from October 12...

Entwistle & Cappucci LLP Files a Securities Class Action Against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC and Pfizer, Inc.

NEW YORK--(BUSINESS WIRE)--Entwistle & Cappucci LLP (“Entwistle & Cappucci”) today announced that its ongoing investigation has led to the filing of a class action (the “Action”) against Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”), Bain Capital Investors, LLC (“Bain”) and Pfizer, Inc. (“Pfizer”) on behalf of a class (the “Class”) consisting of all persons or entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the perio...
Back to Newsroom